These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28978981)

  • 1. Galectin-1 as a novel risk factor for both gestational hypertension and preeclampsia, specifially its expression at a low level in the second trimester and a high level after onset.
    Hirashima C; Ohkuchi A; Nagayama S; Suzuki H; Takahashi K; Ogoyama M; Takahashi H; Shirasuna K; Matsubara S
    Hypertens Res; 2018 Jan; 41(1):45-52. PubMed ID: 28978981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of serum-circulating angiogenic factors within 1 week prior to delivery are closely related to conditions of pregnant women with pre-eclampsia, gestational hypertension, and/or fetal growth restriction.
    Nanjo S; Minami S; Mizoguchi M; Yamamoto M; Yahata T; Toujima S; Shiro M; Kobayashi A; Muragaki Y; Ino K
    J Obstet Gynaecol Res; 2017 Dec; 43(12):1805-1814. PubMed ID: 28929598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma level of hydroxysteroid (17-β) dehydrogenase 1 in the second trimester is an independent risk factor for predicting preeclampsia after adjusting for the effects of mean blood pressure, bilateral notching and plasma level of soluble fms-like tyrosine kinase 1/placental growth factor ratio.
    Ohkuchi A; Ishibashi O; Hirashima C; Takahashi K; Matsubara S; Takizawa T; Suzuki M
    Hypertens Res; 2012 Dec; 35(12):1152-8. PubMed ID: 22786566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of second trimester maternal serum sFlt-1, PlGF and their ratio in the prediction of preeclampsia].
    Gao J; Shen J; Jiang Y; Zhou X; Qi H; Liu X; Liu J; Yang J; Bian X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jan; 49(1):22-5. PubMed ID: 24694913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onset threshold of the plasma levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19-31 weeks of gestation.
    Ohkuchi A; Hirashima C; Takahashi K; Suzuki H; Matsubara S; Suzuki M
    Hypertens Res; 2013 Dec; 36(12):1073-80. PubMed ID: 23966056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased serum strontium levels and altered oxidative stress status in early-onset preeclampsia.
    Barneo-Caragol C; Martínez-Morillo E; Rodríguez-González S; Lequerica-Fernández P; Vega-Naredo I; Álvarez FV
    Free Radic Biol Med; 2019 Jul; 138():1-9. PubMed ID: 31055131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
    Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenic profile and smoking in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort.
    Jääskeläinen T; Suomalainen-König S; Hämäläinen E; Pulkki K; Romppanen J; Heinonen S; Laivuori H;
    Ann Med; 2017 Nov; 49(7):593-602. PubMed ID: 28537456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gestational hypertension as a subclinical preeclampsia in view of serum levels of angiogenesis-related factors.
    Hirashima C; Ohkuchi A; Takahashi K; Suzuki H; Yoshida M; Ohmaru T; Eguchi K; Ariga H; Matsubara S; Suzuki M
    Hypertens Res; 2011 Feb; 34(2):212-7. PubMed ID: 21048778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum soluble LIGHT in the early third trimester as a novel biomarker for predicting late-onset preeclampsia.
    Hirashima C; Ohmaru-Nakanishi T; Nagayama S; Takahashi K; Suzuki H; Takahashi H; Usui R; Shirasuna K; Matsubara S; Ohkuchi A
    Pregnancy Hypertens; 2018 Oct; 14():174-176. PubMed ID: 30527108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel three-step approach for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19-31 weeks of gestation.
    Hirashima C; Ohkuchi A; Takahashi K; Suzuki H; Matsubara S; Suzuki M
    Hypertens Res; 2014 Jun; 37(6):519-25. PubMed ID: 24599015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women.
    Forest JC; Thériault S; Massé J; Bujold E; Giguère Y
    Clin Chem Lab Med; 2014 Aug; 52(8):1169-78. PubMed ID: 24535301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia.
    Ohkuchi A; Hirashima C; Matsubara S; Takahashi K; Matsuda Y; Suzuki M
    Hypertension; 2011 Nov; 58(5):859-66. PubMed ID: 21947468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia.
    Turpin CA; Sakyi SA; Owiredu WK; Ephraim RK; Anto EO
    BMC Pregnancy Childbirth; 2015 Aug; 15():189. PubMed ID: 26303772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
    Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
    Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia.
    Wikström AK; Larsson A; Eriksson UJ; Nash P; Nordén-Lindeberg S; Olovsson M
    Obstet Gynecol; 2007 Jun; 109(6):1368-74. PubMed ID: 17540809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
    J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia.
    Tang P; Xu J; Xie BJ; Wang QM
    Hypertens Pregnancy; 2017 Feb; 36(1):48-52. PubMed ID: 27834501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of preeclampsia with angiogenic biomarkers. Results from the prospective Odense Child Cohort.
    Andersen LB; Dechend R; Jørgensen JS; Luef BM; Nielsen J; Barington T; Christesen HT
    Hypertens Pregnancy; 2016 Aug; 35(3):405-19. PubMed ID: 27159383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.